The Life History of 21 Breast Cancers

Serena Nik‐Zainal(Wellcome Sanger Institute), Peter Van Loo(Wellcome Sanger Institute), David C. Wedge(Wellcome Sanger Institute), Ludmil B. Alexandrov(Wellcome Sanger Institute), Christopher Greenman(University of East Anglia), King Wai Lau(Wellcome Sanger Institute), Keiran Raine(Wellcome Sanger Institute), David Jones(Wellcome Sanger Institute), John Marshall(Wellcome Sanger Institute), Manasa Ramakrishna(Wellcome Sanger Institute), Adam Shlien(Wellcome Sanger Institute), Susanna L. Cooke(Wellcome Sanger Institute), Jonathan Hinton(Wellcome Sanger Institute), Andrew Menzies(Wellcome Sanger Institute), Lucy Stebbings(Wellcome Sanger Institute), Catherine Leroy(Wellcome Sanger Institute), Mingming Jia(Wellcome Sanger Institute), Richard Rance(Wellcome Sanger Institute), Laura Mudie(Wellcome Sanger Institute), Stephen J. Gamble(Wellcome Sanger Institute), Philip J. Stephens(Wellcome Sanger Institute), Stuart McLaren(Wellcome Sanger Institute), Patrick Tarpey(Wellcome Sanger Institute), Elli Papaemmanuil(Wellcome Sanger Institute), Helen Davies(Wellcome Sanger Institute), Ignacio Varela(Wellcome Sanger Institute), David J. McBride(Wellcome Sanger Institute), Graham R. Bignell(Wellcome Sanger Institute), Kenric Leung(Wellcome Sanger Institute), Adam P. Butler(Wellcome Sanger Institute), Jon W. Teague(Wellcome Sanger Institute), Sancha Martin(Wellcome Sanger Institute), Göran Jönsson(King's College London), Odette Mariani(Institut Curie), Sandrine Boyault(Université Claude Bernard Lyon 1), Penelope Miron(Dana-Farber Cancer Institute), Aquila Fatima(Dana-Farber Cancer Institute), Anita Langerød(Oslo University Hospital), Samuel Aparício(University of British Columbia), Andrew Tutt(King's College London), Anieta M. Sieuwerts(Erasmus University Rotterdam), Åke Borg(Lund University), Gilles Thomas(Université Claude Bernard Lyon 1), Anne Vincent Salomon(Institut Curie), Andrea L. Richardson(Brigham and Women's Hospital), Anne‐Lise Børresen‐Dale(Oslo University Hospital), P. Andrew Futreal(Wellcome Sanger Institute), Michael R. Stratton(Wellcome Sanger Institute), Peter J. Campbell(University of Cambridge)
Cited by 1,525Open Access
Full Text

Abstract

Cancer evolves dynamically as clonal expansions supersede one another driven by shifting selective pressures, mutational processes, and disrupted cancer genes. These processes mark the genome, such that a cancer's life history is encrypted in the somatic mutations present. We developed algorithms to decipher this narrative and applied them to 21 breast cancers. Mutational processes evolve across a cancer's lifespan, with many emerging late but contributing extensive genetic variation. Subclonal diversification is prominent, and most mutations are found in just a fraction of tumor cells. Every tumor has a dominant subclonal lineage, representing more than 50% of tumor cells. Minimal expansion of these subclones occurs until many hundreds to thousands of mutations have accumulated, implying the existence of long-lived, quiescent cell lineages capable of substantial proliferation upon acquisition of enabling genomic changes. Expansion of the dominant subclone to an appreciable mass may therefore represent the final rate-limiting step in a breast cancer's development, triggering diagnosis.


Related Papers

No related papers found

Powered by citation graph analysis